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Ay: the lethal yellow (Ay) mutation in the agouti gene produces mice with a
complex phenotype including obesity and a yellow coat color [54].
Body mass index (BMI): weight (in kilograms) divided by the square of height
(in meters). Overweight is defined as BMI >25, and obesity as BMI >30.
Cepfat: homozygous loss-of-function mutations in the carboxypeptidase E gene
result in obesity and hyperglycemia [55].
Diet-induced obesity (DIO): mice with obesity induced by diet, rather than
purely genetic causes [56].
Dominant negative: a mutation that results in a protein that interferes with the
function of the wild type protein, usually through dimerization with the wild
type protein.
Energy balance: energy intake versus energy expended as internally produced
heat and physical activity.
Lepob: disruption of both copies of the leptin gene results in obese,
hyperphagic (over-eating) mice [57].
Leprdb: shares similar features with the Lepob mouse and results from
abnormal splicing of the long, hypothalamic leptin receptor [58].
Linkage disequilibrium (LD) block: linkage disequilibrium is the name given to
the phenomenon whereby alleles at multiple loci appear together more often
than would be expected by chance. This is often measured by r2, which ranges
from zero (unlinked loci) to 1 (complete correlation between loci). An LD block
defines a region within which variable loci are highly correlated (usually r2
>0.8).
Lipolysis: the breakdown of fat (triglycerides) into free fatty acids within body
cells.
Polydactyly: having >10 fingers or toes.
Tagging SNPs: SNPs that can be used as proxy for other, correlated SNPs
(normally with a pairwise correlation of r2 >0.8 (see the definition of linkage
disequilibrium block, above)).
Thermogenesis: heat production. A component of energy expenditure that can
be stimulated by the sympathetic nervous system.In 2007, an association of single nucleotide polymorph-
isms (SNPs) in the fat mass and obesity-associated (FTO)
gene region with body mass index (BMI) and risk of
obesity was identified in multiple populations, making
FTO the first locus unequivocally associated with adi-
posity. At the time, FTO was a gene of unknown function
and it was not known whether these SNPs exerted their
effect on adiposity by affecting FTO or neighboring
genes. Therefore, this breakthrough association inspired
a wealth of in silico, in vitro, and in vivo analyses in model
organisms and humans to improve knowledge of FTO
function. These studies suggested that FTO plays a role
in controlling feeding behavior and energy expenditure.
Here, we review the approaches taken that provide a
blueprint for the study of other obesity-associated genes
in the hope that this strategy will result in increased
understanding of the biological mechanisms underlying
body weight regulation.
Obesity: a growing problem
Overweight and obesity, defined as body mass indices
(BMI) >25 and >30, respectively, are associated with
premature death through increased risk of many chronic
diseases, including type 2 diabetes, cardiovascular disease
and cancer [1]. Over the last three decades, the prevalence
of overweight and obesity have increased rapidly and the
latest World Health Organization (WHO) estimates
suggest that 1.6 billion adults (aged 15 years and over)
were overweight and 400million were obese in 2005. These
figures are predicted to rise to 2.3 billion overweight and
over 700 million obese adults by 2015 (http://www.who.int/
mediacentre/factsheets/fs311/en/index.html). Obesity is
therefore a major international public health threat and
economic burden. Although environmental factors, such as
little physical activity and over-eating, have driven the
recent rise in the numbers of people who are overweight or
obese, genetic factors are estimated to account for 40–90%
of the population variation in BMI [2–4]. It is hoped that
identifying the genetic factors underlying the heritable
risk of obesity will contribute to our basic knowledge of
the biology of energy balance, and might even highlight
molecules and pathways that can be targeted for thera-
peutic intervention. In 2007, single nucleotide polymorph-
isms (SNPs) within the fat mass and obesity-associated
gene (FTO) became the first to be associated reproduciblyCorresponding author: Barroso, I. (ib1@sanger.ac.uk)
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genetic association between SNPs in the FTO gene region
and BMI in humans, the various studies undertaken and
the challenges in progressing from a genetic association to
new biological insight. We also provide an overview of
possible future directions for research in this field.
Genetic studies of common obesity
Before 2007, despite huge efforts using genome-wide link-
age studies and candidate gene association studies, no
genetic variation had been unequivocally associated with
BMI and risk of obesity in population studies [5]. In recent
years, however, genome-wide association studies (GWAS),
which test the correlation between SNPs across the entire
genome and trait variation in a sample of individuals, have
succeeded in identifying variants associated reproducibly
with complex traits. GWAS for type 2 diabetes (T2D)
detected strong association between common SNPs in
the FTO region and risk of T2D [6–8]. However,Tub: tubby mice exhibit adult-onset obesity due to mutation in the Tub gene
[59,60]. The function of the Tub gene is not entirely clear.
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Box 1. Fine-mapping association between FTO and obesity
Whereas linkage disequilibrium (LD) aids the discovery of genetic
associations, because the investigator does not need to test all
variant(s) in a given genomic region to detect association signals, it is
a hindrance to fine-mapping efforts. This is because high correlation
between SNPs makes it difficult to distinguish between the effects of
true causal variants and correlated non-causal variants. Conse-
quently, it is not clear which causal variant(s) underlie the association
between BMI and SNPs in FTO (which reside within a 47 kb LD block).
So far, fine-mapping attempts have focused on selecting tagging
SNPs within the associated genomic region and genotyping or
imputing these in additional study populations of different ancestry
[6,9,15,19,25,26]. The advantage of using study cohorts of different
ancestry lies in their varying patterns of LD. For example, LD is
generally weaker in populations of African descent. Two recent
studies attempted to refine the association signal from FTO in
individuals of African ancestry, but none of the SNPs tested was
associated with obesity in both cohorts [6,15]. Fine-mapping studies
have been done with Japanese [19] and Old Amish Order participants
[25]. Some of the SNPs associated with BMI in these populations have
overlapped with associated SNPs in Europeans but the SNPs most
strongly associated with BMI vary between cohorts. For example, the
strongest SNP (rs1861868) in the Old Amish Order study had not been
previously associated with obesity. This might reflect interstudy
differences in the causal variant(s) or differences in levels of LD
between tested SNPs and the same causal variant(s). It is worth
mentioning that in a European fine-mapping study cohort, three of
the four most significantly associated SNPs (rs17817449, rs3751812
and rs1421085) were in putative functional regions (based on
conservation and predicted impact on regulatory domains) but these
SNPs were highly correlated with each other and their effects could
not be distinguished [9]. Interestingly, despite an earlier demonstra-
tion that associated SNPs in the FTO region were likely to be tagging
the same signal rather than multiple, independent signals [6], Tonjes
et al. discovered an independent association with BMI from SNPs in
FTO introns 2 and 3, downstream of the original signal, in Sorbian
individuals [26]. This suggests that this genomic region might harbor
multiple variants that influence susceptibility to obesity, which might
complicate future fine-mapping attempts.
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FTO SNPs and T2D was mediated by an association with
BMI [7]. The association between FTO SNPs and BMI and
the risk of being overweight or obese has been confirmed in
multiple populations [6,7,9–27]. The effect of FTO SNPs on
BMI is modest, with those individuals homozygous for the
risk allele weighing, on average, 3 kg more than those
homozygous for the protective allele [7].
Association does not necessarily mean causation. BMI-
associated SNPs lie within a 47 kilobase (kb) linkage
disequilibrium (LD) block encompassing parts of the first
two introns as well as exon 2 of FTO. Thus, the association
signal could be due to correlation between FTO intronic
SNPs and variation elsewhere in the gene or control
elements of other genes. Indeed, the transcription start
site of the retinitis pigmentosa GTPase regulator-interact-
ing protein 1-like (RPGRIP1L) gene (homolog of murine
Rpgrip1l, also known as Ftm) is in close proximity
(400 bp) to the 5’ end of FTO [7]. It is therefore possible
that SNPs in FTO are associated with obesity through an
effect on RPGRIP1L. Efforts to fine-map the association
signal to causative variant(s) are underway (Box 1).
Since the discovery of the FTO signal, additional GWAS
have succeeded in identifying many additional novel
obesity loci [12,28–33]. Before these findings can be con-
verted into clinical benefits, however, it is necessary to
determine the biological mechanisms by which confirmed
obesity susceptibility variants impact BMI.
Early insights into FTO function
When associations between SNPs at FTO and BMI were
first discovered [6,7,9], little was known about the function
of the FTO gene product. Fto was first identified in the
mouse by positional cloning [34] as one of the genes within
a 1.6 megabase deletion on chromosome 8 responsible for
the Fused toes (Ft) phenotype [35]. Mice homozygous for
the deletion died mid-gestation and exhibited severe mal-
formations of the head and face, central nervous system
(CNS) developmental defects [36,37], randomized left–
right asymmetry [38], polydactyly and growth retardation.
Heterozygotes displayed fused toes and enlargement of the
thymus [34,35]. However, no obesity or thinness wasreported in these mice. Nevertheless, as Fto was only
one of six genes deleted in the Ft mouse (the others were
the Iroquois B cluster of genes, Irx3, Irx5 and Irx6, and two
other genes, Fts and Rpgrip1l), it was not known which, if
any, of these phenotypic manifestations were due to Fto
deficiency. Interestingly, a phenotype similar to that of Ft
mice was seen in a human patient harboring a small
chromosomal duplication on 16q12.2, a region that
includes the FTO gene [39].
In silico and in vitro analyses of FTO
Clues from the Ft mouse and human chromosomal dupli-
cation were not sufficient to shed light on the specific
effects of FTO. Moreover, FTO was not annotated in the
public databases as having homology to any other known
gene. The discovery that this mysterious gene was associ-
ated with human obesity [6,7,9] inspired further research
aimed at elucidating its functional properties. In silico
analyses of the human FTO sequence revealed homologs
in other vertebrates (from fish to mammals) and marine
algae (from unicellular photosynthetic picoplankton to
multicellular seaweed) [40–43]. Sequence analysis showed
that FTO shares features with Fe (II) and 2-oxoglutarate
(2OG) oxygenases [41,43]. These enzymes catalyze oxi-
dative reactions on multiple substrates using non-heme
iron as a co-factor and 2OG as a co-substrate [41,43].
Within this superfamily, FTO ismost similar to theEscher-
ichia coli enzyme AlkB and its eukaryotic homologs, which
can repair DNA methylation damage by hydroxylating
methyl groups on the DNA leading to their removal [44].
These data suggest that FTO might act as a demethylase.
Sequence analysis also predicted that human FTO and its
vertebrate homologs are globular proteins that carry a
nuclear localization signal and are unlikely to be targeted
to membranes or organelles [42,43]. This prediction was
confirmed by in vitro studies, which showed that murine
Fto is indeed a 2OG oxygenase that can catalyse nucleic
acid demethylation [41]. It is conceivable, therefore, that
the nucleic acid demethylation activity of FTO might
regulate the expression of genes involved in metabolism
and that dysregulation of this process might lead to
obesity.267
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Caution is always recommended when interpreting gene
function from in vitro studies, as the activity of molecules
might differ in whole organisms and under different con-
ditions: therefore, animal models are used to further elu-
cidate in vivo function.
Wild type Fto expression in fed, fasted and obese rodent
models
Early studies of mouse Fto and human FTOmRNA expres-
sion showed that both are ubiquitous, with particularly high
levels of expression in the brain and hypothalamus [7,9,34].
Thesewere intriguing results because thehypothalamus is a
key site for regulation of energy balance, and genes respon-
sible for monogenic obesity function in the hypothalamus to
regulate appetite [45]. Further studies of FtomRNA expres-
sion in wild-type rodent tissues confirmed its ubiquitous
expression, with high levels of expression in hypothalamic
regions known to play important roles in the regulation of
energy intake and expenditure, and suggested that expres-
sion of Fto might be regulated by nutritional status [40,41].
Inthe fastedstate (that is,whenthere isa strongstimulus for
eating), mice exhibit a significant reduction in hypothalamic
FtomRNAexpression compared to fed controls. This effect is
not rescued by supplementation with the anti-starvation
hormone leptin [41,46], which suggests that the reduced
hypothalamic Fto expression observed during fasting is
independent of leptin levels. In support of this conclusion,
hypothalamicFto expression is reduced in fasted Lepobmice
(which lack leptin) compared to fed Lepob and control mice
[46]. These studies suggest thatFto is downregulated during
fastingandupregulatedduring feeding,andthatvariation in
Fto resulting in decreased expression or activity might pro-
vide a signal that promotes feeding and obesity.
In contrast to the mouse data, Fto expression was
increased significantly in the hypothalamus of food-
deprived and food-restricted rats [40]. Two possible
reasons have been suggested to explain this discrepancy:
different sensitivity to starvation in mice and rats, or
different times at which samples were taken in the two
studies. In rats, in addition to hypothalamic expression,
Ftowas widely and consistently expressed in brain regions
related to circadian rhythmicity [40] and therefore its
expression might vary at different times of day. Upregula-
tion of hypothalamic Fto in fasted rats suggests that high
levels of Fto protein might stimulate food intake, which is
the opposite effect predicted from its expression in wild
type mice [40]. More recent data in rats disagree with this
study, finding that over-expression of Fto mRNA in the
hypothalamus decreased food intake, whereas a 40%
decrease in Fto protein led to increased food consumption
[47]. These data might contrast with previous data in rats
because the measurements and manipulation of Fto were
limited to a specific region of the hypothalamus (the arc-
uate nucleus), where the expression of Fto is very high. To
date, all studies of rodents have been done over prolonged
periods of fasting, which might better resemble starvation
rather than fasting and hence some of the observations
might reflect that. There is a need for studies with shorter
fasting times in rodents to better understand the regula-
tion of Fto expression during this time.268Given that variants in FTO are associated with human
obesity and thatFtomRNA levels appear to be regulated in
response to feeding and fasting, its expression was deter-
mined in relation to changes in obesity. In six mouse
models of obesity (Ay, Lepob, Leprdb, Cepfat, tub and mice
with diet-induced obesity (DIO); Glossary), hypothalamic
Fto expression did not differ significantly from that in wild
type mice [46]. This study assessed Fto gene expression in
other metabolically relevant tissues, such as fat (adipose)
tissue. Adipose tissue acts as a fat store and synthesizes
and secretes a variety of proteins (such as leptin) that
influence appetite and metabolism at distal sites. Expres-
sion of Fto in mesenteric fat was reduced significantly
compared to wild type in all mouse models except DIO.
This is interesting because murine Fto gene expression
was shown to be downregulated under fasting conditions,
suggesting that obese mouse models mimic the fasted
state, possibly contributing to their over-eating.
Fto expression differs under feeding and fasting con-
ditions and displays tissue-specific differences in mouse
models of obesity, but it is not known whether these
differences are the cause or the consequence of obesity.
To further investigate whether differences in Fto expres-
sion or function can cause increases or decreases in fat
mass, mice harboring Fto mutations were generated.
Mouse models of Fto deficiency
Two mouse models of Fto deficiency have been reported: a
null mutation (Fto/) resulting in the complete absence of
Fto protein expression [48], and a partial loss-of-function
mutation with reduced Fto protein levels (Table 1) [49].
The partial loss-of-function Fto mouse model carries a
point mutation resulting in a change in the amino acid
sequence from isoleucine to phenylalanine at position 367
(I367F). Although this residue is outside the catalytic core,
it is located within a 20 amino acid block conserved
throughout vertebrates that defines a new functional
domain [49]. In vitro experiments demonstrated that,
although the full-length I367F protein was correctly loca-
lized to the nucleus, it displayed lower levels of expression
in mammalian cells and resulted in reduced catalytic
activity, possibly through altering the Fto dimerization
state. However, the exact role of different Fto dimerization
states in energy balance is poorly understood. The mutant
Fto I367F protein retains partial function, which is likely
to account for some of the observed differences between the
phenotypes of these two animal models. Namely, although
both models demonstrated reduced body weight and fat
mass, this starts early in life in the case of Fto/ mice,
whereas weight reduction in FtoI367F mice has a maturity-
onset. Also, there is no discernible phenotype in the Fto
null heterozygous mice, whereas the phenotype of the
heterozygous FtoI367F is very similar to that of their homo-
zygous mutant littermates. The importance of I367 in
dimerization might help explain why the FtoI367F hetero-
zygous mice have a phenotype: the I367F substitution
might have a dominant negative effect by disrupting the
function of wild type Fto through formation of heterodi-
mers. The weight reduction observed in the two models is
also very different: Fto null mice have a 30–40% weight
reduction compared to wild type littermates, whereas the
Table 1. Comparison of the effects of FTO variants in mouse and human
Theme FtoS/S mouse* FtoI367F mouse** FTO R316Q in human* FTO variation in human References
Pre- and
post-natal
body weight
No effect on pre-natal
development but
decreased body weight
is apparent from an
early age, with
reduction in fat mass
more pronounced than
reduction in lean mass.
Reduced weight gain
on high-fat diet
No effect on pre-natal
development but males
exhibit maturity-onset
reduction in body
weight, attributable
to decreased fat
mass. Reduced
weight gain on
high-fat diet
Parents of the probands
are not clinically obese,
nor reported to be
excessively thin
Robust association
between FTO SNPs and
fat mass in children, and
a trend towards increased
birth weight and mass in
relation to height in
newborns carrying obesity
risk alleles, though this
was statistically significant
in only one study
[4,7,9–11,15,18,
48–50,66–72]
Post-natal
death
Post-natal death
occurred more
frequently
No difference in
post-natal mortality
Death from intercurrent
infection or an
unidentified cause
occurred within
30 months of age
Association with post-natal
mortality but less associated
with disease incidence,
implying a reduced ability to
cope with disease in risk
allele carriers
[48–50,73]
Growth
retardation
Growth retardation
from post-natal
day 2
No growth
retardation
All affected individuals
suffered from post-natal
growth retardation
No association with
height
[7,48–50,74]
Development No other gross
developmental
abnormality
No other gross
developmental
abnormality
Microcephaly, severe
psychomotor delay,
functional brain deficits,
and facial dysmorphism.
Structural brain
malformations, cardiac
defects, genital
anomalies, and cleft
palate observed
in some patients
No difference reported [48–50]
Adipose
tissue mass
and adipokines
Decrease in adipose
tissue mass, leptin
and increase
in adiponectin
Decrease in adipose
tissue mass. Higher
leptin secretion per
unit of body fat. No
difference in
adiponectin
No difference
reported
Association driven by
general changes in
fat mass, not lean mass.
No convincing association
with leptin or adiponectin
[7,10,11,16,22,
48–50,75–77]
FTO expression
and function
Abolished
expression in
all tissues tested
Reduced expression in
mammalian cells, and
disrupted dimerization
and catalytic activity
of Fto
FTO R316Q is
catalytically inactive.
This amino acid
substitution does not
affect FTO nuclear
localization
No reported association
between FTO SNPs
and FTO expression.
However, there is some
evidence that FTO
expression is enhanced
in adipose tissue of obese
individuals. No reported
effects on catalytic activity
[27,48–50,
77–80]
Sex
differences
Reduced body
weight more
pronounced in
males, but amongst
heterozygotes only
females showed
reduced body
weight at 20 weeks
Only male FtoI367F
mice exhibited
reduced weight
at 12 weeks
No difference
reported
Overwhelmingly no
evidence for gender
difference in the effect of
FTO SNPs, despite hints
of a stronger effect in girls
[7,9,48–50,66]
Energy
intake
Higher food intake
in Fto/ mice
relative to lean
mass
No difference in
food intake between
FtoI367F mutant and
control mice
No difference
reported
Some studies report no
association with food
intake, though in other
studies (especially large
studies with children
where diet is reported
by parents or through
feeding experiments)
there have been statistical
associations with
increased energy intake
or preference for energy
dense foods, and
one report of an
interaction with FTO
genotype on BMI
[11,13,48–50,
81–91]
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Theme FtoS/S mouse* FtoI367F mouse** FTO R316Q in human* FTO variation in human References
Energy
expenditure
Increased energy
expenditure
Increased energy
expenditure
No difference
reported
No association with measures
of energy expenditure. No
correlation between skeletal
muscle or adipose tissue FTO
expression and energy
expenditure
[11,13,48–50,
78,81,84,92,93]
Physical
activity
Significantly
decreased
physical activity
No difference in
physical activity
No difference
reported
No association with physical
activity, but reported
interaction between genotype
and physical activity on BMI
[10,25,48–50,67,
82,90,91,94,95]
Glucose
tolerance
and insulin
sensitivity
Mild improvement
in insulin sensitivity
(probably as a
consequence of
leanness)
No convincing
difference in glucose
tolerance or
insulin sensitivity
No difference
reported
Overwhelmingly the evidence
suggests no association with
glucose tolerance or insulin
sensitivity of FTO SNPs, or
FTO expression
[12,14,16,20–24,
48–50,71,78,
80,96]
Lipids Triglycerides and
high-density
lipoprotein (HDL)
cholesterol
increased in FtoI367F
mice
No difference
reported
Some evidence for
association with elevated
triglycerides and
cholesterol
[17,48–50,
80,82,96]
Other gene
expression
Npy mRNA induction
was blunted and
Pomc mRNA
repression
exaggerated in
fasted FtoS/S mice
Altered expression of
some genes involved in
inflammation, fatty acid
catabolism and
synthesis, carbohydrate
metabolism and the
ER stress response
in FtoI367F mice and
Npy expression was
lower in fed mutant
mice
No difference
reported
Not examined for FTO
SNPs, but FTO expression
correlated with oxidative
phosphorylation genes
involved in mitochondrial
function and their regulator,
PGC1A, as well as GLUT4
mRNA. Some evidence
for a role of FTO in
inflammation and stress
response
[6,48–50,78,97]
*Cells refer to the homozygous mutant unless otherwise stated.
**Cells refer to both the homozygous mutant and heterozygous mice unless otherwise stated.
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Another significant difference between the two models is
that only Fto/ mice exhibited growth retardation and
early perinatal death [48,49]. On a high-fat diet, both
models exhibited reduced weight gain and reduced white
adipose tissue compared to controls [48,49]. These findings
indicate that disruption of Fto activity can protect against
diet-induced obesity.
These studies then investigated whether reduced
growth and adiposity in the Fto mouse models is due to
decreased energy intake, increased energy expenditure or
both. Compared to wild type littermate controls, there was
no difference in absolute food intake in Fto-deficient mouse
models [48,49]. However, Fto/ mice ate relatively more
given their reduced body weight and size [48]. These
results demonstrated that reduced fat mass in Fto-
deficient mice was not due to reduced food intake. How-
ever, both models exhibited higher levels of energy expen-
diture (higher metabolic rate) such that overall the
animals gained less weight and were protected from
obesity [48,49]. The increase in energy expenditure was
unrelated to levels of physical activity (indeed, paradoxi-
cally there was a reduction in locomotor activity in Fto null
mice but this was not observed in the FtoI367F mutant) but
was potentially mediated by increased sympathetic ner-
vous system (SNS) activity, a system that originates in the
spinal cord with projections to peripheral tissues and is
used by the hypothalamus to regulate energy homeostasis270[48,49]. This increased SNS activity might be promoting
lipolysis and thermogenesis in adipose tissue and muscle.
Microarray analysis of white adipose tissue, liver and
skeletal muscle detected some differences in gene expres-
sion in FtoI367F mutants compared to wild type mice [49].
As expected, given the known link between excess adipose
tissue and induction of inflammatory responses, in mutant
mice with reduced white adipose tissuemass, expression of
multiple genes involved in inflammation was downregu-
lated in adipose tissue. In contrast, upregulation in adipose
tissue of some genes involved in fatty acid catabolism
might explain, in part, the lower fat mass. Upregulation
of genes involved in fatty acid synthesis in adipose tissue
and upregulation of fatty acid synthase and genes involved
in carbohydrate metabolism in muscle might reflect sec-
ondary adaptations to a lower supply of fatty acid (due to
smaller fat reserves). Indeed, FtoI367F mutants demon-
strated increased carbohydrate metabolism relative to
fat metabolism. Hypothalamic neuropeptide expression
did not differ between wild type and mutant in the fasted
state, but Npy expression was lower in fed mutant mice.
Given that increased Npy stimulates food intake, this
finding suggests that Fto-deficient mice are more sensitive
to satiety and are thereby protected from obesity through
over-eating. A blunting of Npy induction was seen inFto/
mice in the fasted state, lending support to the suggestion
that Fto promotes Npy expression [48]. It is conceivable
that the nucleic acid demethylation activity of Fto might
Review Trends in Genetics Vol.26 No.6provide amechanism throughwhich it affects expression of
these other genes.
The phenotypic characterization of both the Fto/ and
FtoI367F mice support the idea that association of FTO
SNPs with human obesity arises via regulatory or func-
tional effects on FTO rather than other genes in the region.
Although the Fto null mutation could impact regulation of
other genes, the non-synonymous mutation in FtoI367F
mice is most likely to exert its functional effects on Fto
alone [49]. Furthermore, both models suggest that alleles
associated with increased risk of obesity will cause up- or
dysregulation of FTO and that inhibition of FTO might
protect against obesity [48,49].
The relevance and utility of functional FTO data for
humans
Although animalmodels are useful tools to investigate gene
function, they do not necessarily reflect the situation in
humans. Recently, for example, a loss-of-function non-
synonymousmutation resulting in an arginine to glutamine
change at position 316 in FTO was reported to segregate
with an autosomal recessive disease in a large Palestinian
Arab consanguineous family with nine affected members
[50]. The syndrome includes post-natal growth retardation,
head and face dysmorphism, severe psychomotor delay,
functional brain deficits and, in some patients, brain mal-
formations, cardiac defects, genital abnormalities and cleft
palate. These developmental characteristics seem more
similar to the Ftmouse than either of theFtomousemodels.
This discrepancy between the effects of human and mouse
mutations (Table 1) might reflect differences between the
actions of FTO in humans and mice or, alternatively,
multiple roles for FTO that are disparately affected by
themouse and humanmutations. This is an intriguing area
of investigation for the future and results from different
animal models (e.g. transgenic Fto over-expression in mice)
are eagerly anticipated. The lack of clinical obesity in
patients carrying R316Q and family members is perhaps
consistentwith the relationship between loss ofFto function
and leanness in mice. More recently, however, loss-of-func-
tionheterozygousmutations inFTOwere found in both lean
and obese humans, suggesting that haploinsufficiency does
not protect against obesity completely, though the relation-
ship might be complicated by other obesity-promoting fac-
tors [51]. Other differences between the effects of mouse Fto
mutations and humanFTO SNPs (Table 1) are perhaps less
surprising because FTO SNPs in the human population are
likely not strong loss-of-function variants, particularly as
the most strongly associated SNPs are intronic and there-
fore postulated to have an effect on gene regulation.
Concluding remarks and future perspectives
Despite recent progress, the mechanism by which SNPs in
FTO influence human body mass remains elusive. Multiple
processes could plausibly contribute to the risk of obesity,
including neurological circuits governing appetite and
whole-body energy expenditure, as well as peripheral path-
ways involved in energy expenditure. Loss-of-Fto function
appears to reduce fat mass inmice, at least in part, through
increased energy expenditure but not decreased energy
intake [48,49]. However, the study of intermediate pheno-types inhumans showed thatFTOSNPsare associatedwith
appetite and food intake but not energy expenditure
(Table 1). Interestingly, data from rodents suggested that
Fto might affect neuropeptide Y expression in the hypo-
thalamus, which in turn is known to impact feeding beha-
vior.An investigationof the association betweenFTOSNPs/
expression and neuropeptide levels in human hypothala-
mus might therefore provide a mechanism for the modula-
tory effect of FTO SNPs on appetite, although it would be
challenging to obtain human hypothalamic material.
Another potential area of future investigation is the role
ofFTO in circadianrhythms, given itsexpression inrelevant
brain regions in rats [40]. Aberrant circadian rhythms have
been linked to metabolic disease and obesity [52].
At present, the strongest associations between FTO
SNPs and BMI belong to intronic SNPs, which might have
a role in the regulation of FTO and/or nearby genes. It is
important to note, however, that associated SNPs are not
necessarily the causal SNPs underlying the association. It
is possible that fine-mapping the causal variant(s) could
shed light on the biological mechanism impacting body
mass, for example by determining whether the causal
variant(s) change the amino acid sequence of FTO or
whether they lie within a control element affecting expres-
sion of other genes in the region, such as RPGRIP1L.
However, fine-mapping the association signal might be
difficult because the obesity-associated SNPs lie within a
47 kb LD block in which the effects of causal variant(s)
could be indistinguishable from other, highly correlated
proxies. Under these circumstances it might prove more
important to understand the biological effect of the risk
haplotype (rather than the causal variants themselves) on
genes and pathways. FTO obesity-associated SNPs do not
appear to influence FTO expression but could be investi-
gated for their effect on expression of its neighboring gene
RPGRIP1L. Nevertheless, there is now some evidence to
suggest that the associations with BMI are indeed
mediated through FTO (Box 2); however, joint effects via
FTO and RPGRIP1L, or other genes, have not been dis-
missed completely. A recent report suggested that the
obesity-associated FTO region contains highly conserved
non-coding elements that might be controlling expression
of IRX3 (encoding a transcription factor important in de-
velopment). Though none of the obesity-associated SNPs
fall within these elements, the possibility that the associ-
ation signal results from correlation with causal variant(s)
within these regions has not been excluded [53].
It is clear that the journey undertaken by FTO has
generated many questions as well as answers. Perhaps
themost important lesson from the extensive work on FTO
over the last three years is the promise that other obesity
loci identified byGWAS could lead to new understanding of
the underlying biology of human adiposity. Despite the
small effect sizes and predictive value of the common
variants identified to date, these hits often represent pre-
viously unsuspected obesity genes. The story of FTO
research provides valuable lessons for the study of other
obesity-associated genes. Ultimately, it is hoped that
knowledge of susceptibility gene function will highlight
novel genes and molecules that could be targeted for
therapeutic intervention. For example, the data presented271
Box 2. FTO or RPGRIP1L?
Given the close proximity between FTO and RPGRIP1L, it is possible
that SNPs in FTO are associated with obesity through a direct
regulatory effect on RPGRIP1L or an indirect effect (through linkage
disequilibrium with RPGRIP1L or with RPGRIP1L regulatory site
variation) on RPGRIP1L function. For example, the obesity-asso-
ciated FTO SNP, rs8050136, lies within a Cut-like 1 (CUTL1)
transcription factor binding site. CUTL1 preferentially binds the
rs8050136 allele associated with protection against obesity [46].
Short interfering (si) RNA-mediated knockdown of CUTL1 in
fibroblasts decreased both FTO and RPGRIP1L expression [46].
RPGRIP1L is located in the basal body of cilia, where it regulates
sonic hedgehog (SHH) signaling [61]. Ciliary defects have been
associated with obesity in mice and humans [62,63]; indeed, the
disruption of genes involved in cilia formation or maintenance leads
to obesity [62,63]. It is therefore possible that human obesity is
influenced by FTO SNPs via an effect on RPGRIP1L expression and
ciliary function. However, several pieces of evidence suggest that
this association is driven by a direct effect on FTO:
(1) Mice homozygous for a targeted mutation in Rpgrip1l have a
phenotype reminiscent of the Ft mouse [34], with head and facial
abnormalities, disruption of CNS development, disturbances of
left–right asymmetry, and polydactyly [61]; but no difference in
adiposity has been reported. In contrast, mouse models of Fto
deficiency exhibit reduced fat mass and body weight [48,49].
(2) Mutations in human RPGRIP1L result in ciliopathies, Joubert
syndrome (JBTS) and Meckel syndrome (MKS) [64,65], but no
difference in adiposity compared to the general population has
been reported.
(3) Four known RPGRIP1L SNPs lack an association with either
obesity or related traits [66].
(4) Rpgrip1l mRNA expression is normal in an Fto-deficient mouse
model which exhibits reduced body weight and fat mass [48]
(5) Fasting is associated with decreased Fto, but not Rpgrip1l,
expression in mesenteric fat in mice [46].
Review Trends in Genetics Vol.26 No.6in this review indicate thatFTO deficiency protects against
obesity. However, the devastating effects of a loss-of-func-
tion non-synonymous mutation in FTO in a human family
emphasizes that care should be taken in developing drugs
to alleviate obesity by reducing the expression or inacti-
vating catalytic activity of FTO [50]. Clinical and transla-
tional effects should not be expected in the near future but
GWAS and subsequent investigation of obesity genes
promises exciting new insights into common obesity in
the next few years.
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